Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound

Evaluation of the Accuracy of Liver Lesion DCEUS Quantification With Respiratory Gating

“…For example in a clinical study on liver lesion DCEUS quantification by Averkiou et al [10] the response of patients to treatment was detected as a mean change in the wash-in time ratio quantification parameter of 17% after the first treatment. Zocco et al [30] found significant changes from the baseline of -20% and -25% in the AUC and PI respectively for patients that had a response to hepatocellular carcinoma treatment. Both Averkiou et al and Zocco et al used respiratory gating to improve the accuracy of their quantitative analysis.…”

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

“…Some small cohort studies evaluated the useful of dynamic contrast-enhanced ultrasound (DCE-US) to predict early tumor response to sorafenib in patients with advanced HCC [151][152][153] . In a Japanese prospective monocentric study, a total of 37 patients with advanced HCC treated with sorafenib were evaluated using DCE-US, before treatment and on days 7, 14 and 28 of treatment [152] .…”

“…Early decrease of tumor vascularity [152] DCE-US 37 Prospective Sorafenib Tumor vascularity decreases and blood volume within seven days trends towards better PFS and OS These studies enrolled small cohort of patients hampering adequate interpretation. However, DCE-US remains a promising noninvasive imaging, but operator dependent, to predict response in patients with HCC treated with sorafenib and larger cohort of patients should be evaluated Zocco et al [153] 28…”

Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment

“…Between the parameters analysed PI, AUC and Tp showed a significant reduction soon after the beginning of therapy with sorafenib in most of the patients reaching long-term stable disease (Figure 2). Moreover, a relationship was found between D-CEUS variables and improved clinical outcome such as prolonged OS and PFS [53] . Some researchers evaluated the usefulness of DCEUS in the quantification of liver parenchymal per fusion for the early detection of major adverse events in patients with advanced HCC treated with sorafenib.…”